← Leaderboards
Paul J Limburg
Mayo Clinic Coll Of Medicine, Rochester
$13,911,134
Attributed
$13,911,134
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$13,911,134 · 6
By mechanism
N01$11,929,946 · 3
R01$1,405,123 · 1
K07$564,246 · 1
M01$11,819 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Kenneth K Wang$8,863,249
- Lewis R Roberts$8,981,499
- Yvonne Romero$764,632
- Noralane Morey Lindor$16,138,028
- Vijay H Shah$27,167,769
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyClinical TrialsBaseCancer PreventionDesignProtocols DocumentationDoseProgramsCancer RiskContractorParticipantPreventViral Load ResultResponseStainsChemopreventionPreventiveHepatitis CPreventionDivision Of Cancer PreventionNeoplasm /Cancer EpidemiologyMucous MembraneClinically RelevantMalignant Neoplasms
Grant awards (31)
CORE INFRASTRUCTURE SUPPORT$369,112
N01 · FY2019 · CA · contact PI
PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26$92,891
N01 · FY2019 · CA · contact PI
PHASEI/II TRIAL OF A THERAPEUTIC DNA VACCINE FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION;$84,697
N01 · FY2019 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT$848,703
N01 · FY2018 · CA · contact PI
PHASEI/II TRIAL OF A THERAPEUTIC DNA VACCINE FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION;$170,562
N01 · FY2018 · CA · contact PI
PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26$33,280
N01 · FY2018 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT$855,261
N01 · FY2017 · CA · contact PI
CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26$96,186
N01 · FY2017 · CA · contact PI
CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PHASEI/II TRIAL OF A THERAPEUTIC DNA VACCINE FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION;HHSN261201200042I; TASK ORDER HHSN26100006; 09/09/2014 09/08/2016$86,842
N01 · FY2017 · CA · contact PI
IGF::OT::IGF IGF CORE INFRASTRUCTURE SUPPORT$842,944
N01 · FY2016 · CA · contact PI
IGF::OT::IGF IGF CORE INFRASTRUCTURE SUPPORT$797,722
N01 · FY2015 · CA · contact PI
IGF::OT::IGF R&D- DOSE DE-ESCALATION TRIAL TO IDENTIFY THE LOWEST COMMERCIALLY AVAILABLE DOSE OF LINACLOTIDE THAT MAINTAINS BIOACTIVITY IN RECTAL MUCOSA$38,280
N01 · FY2015 · CA · contact PI
CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26$471,677
N01 · FY2014 · CA · contact PI
CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PHASEI/II TRIAL OF A THERAPEUTIC DNA VACCINE FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION;HHSN261201200042I; TASK ORDER HHSN26100006; 09/09/2014 09/08/2016$407,260
N01 · FY2014 · CA · contact PI
HHSB26120120000421 DOSE-DE ESCALATION/ESCALAATION TRIAL TO IDENTIFY THE LOWEST COMMERCIALLY AVAILABLE DOSE OF LINACLOTIDE THAT MAINTAINS BIOACTIVITY IN RECTAL MUCOSA (PROTOCOL MAY2012-00-01 09/24/201$209,816
N01 · FY2014 · CA · contact PI
Phase 1 and Phase 2 Clinical Trials of Agents for Cancer Prevention$2,196,000
N01 · FY2011 · CA · contact PI
Molecular Epidemiology of Colorectal Cancer Subtypes$76,001
R01 · FY2010 · CA · contact PI
Phase 1 and Phase 2 Clinical Trials of Agents for Cancer Prevention$2,071,000
N01 · FY2009 · CA · contact PI
Molecular Epidemiology of Colorectal Cancer Subtypes$190,878
R01 · FY2009 · CA · contact PI
Molecular Epidemiology of Colorectal Cancer Subtypes$326,923
R01 · FY2008 · CA · contact PI
PHASE 1 AND PHASE 2 CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS$2,257,713
N01 · FY2007 · CA · contact PI
Molecular Epidemiology of Colorectal Cancer Subtypes$140,450
R01 · FY2007 · CA · contact PI
Molecular Epidemiology of Colorectal Cancer Subtypes$383,486
R01 · FY2006 · CA · contact PI
PHASE 1 AND PHASE 2 CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS --261035000$0
N01 · FY2006 · CN · contact PI
Molecular Epidemiology of Colorectal Cancer Subtypes$287,385
R01 · FY2005 · CA
Insulin, the IGF Axis, and Colorectal Neoplasia$125,388
K07 · FY2005 · CA
Insulin, the IGF Axis, and Colorectal Neoplasia$125,388
K07 · FY2004 · CA
Pre-Endoscopy Survey of Risk Factors for GI Conditions$11,819
M01 · FY2004 · RR
Insulin, the IGF Axis, and Colorectal Neoplasia$125,388
K07 · FY2003 · CA
Insulin, the IGF Axis, and Colorectal Neoplasia$62,694
K07 · FY2002 · CA
Insulin, the IGF Axis, and Colorectal Neoplasia$125,388
K07 · FY2001 · CA